Skip to main content
logo
Veracyte, Inc. (VCYT)
NASDAQ: VCYT · Real-Time Price · USD
36.08
+0.75 (2.12%)
At close: Oct 31, 2025, 4:00 PM EDT
36.91
+0.83 (2.30%)
After-hours: Oct 31, 2025, 6:12 PM EDT

Company Description

Veracyte, Inc. operates as a diagnostics company in the United States and internationally.

The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis.

It is also developing the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008.

Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Veracyte, Inc.
Veracyte logo
CountryUnited States
Founded2006
IPO DateOct 30, 2013
IndustryDiagnostics & Research
SectorHealthcare
Employees824
CEOMarc Stapley

Contact Details

Address:
6000 Shoreline Court, Suite 300
South San Francisco, California 94080
United States
Phone650 243 6300
Websiteveracyte.com

Stock Details

Ticker SymbolVCYT
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001384101
CUSIP Number92337F107
ISIN NumberUS92337F1075
Employer ID20-5455398
SIC Code8071

Key Executives

NamePosition
Marc StapleyChief Executive Officer
Rebecca ChambersChief Financial Officer
Keith GligorichChief Operating Officer

Latest SEC Filings

DateTypeTitle
Oct 6, 2025144Filing
Oct 1, 2025144Filing
Oct 1, 2025144Filing
Oct 1, 2025144Filing
Sep 19, 2025144Filing
Sep 4, 2025144Filing
Aug 12, 2025SCHEDULE 13G/AFiling
Aug 12, 2025SCHEDULE 13G/AFiling
Aug 7, 202510-QQuarterly Report
Aug 6, 20258-KCurrent Report
View All SEC Filings